CorMedix (CRMD) Q3 2025: Net Income Hits $108.6M, FY25 Guidance Raised to $390–$410M — Nov 12, 2025
CorMedix Inc. (NASDAQ: CRMD) reported a profitable third quarter and lifted full‑year guidance today as momentum in DefenCath and contributions from the Melinta portfolio accelerated growth. TradingView What happened CorMedix said third‑quarter 2025 net revenue came in at $104.3 million (pro forma $130.8 million), fueled by higher‑than‑expected outpatient DefenCath utilization and partial‑quarter sales from the Melinta portfolio. The company posted net income of $108.6 million and Adjusted EBITDA of $71.9 million for the period. Management raised full‑year 2025 pro forma net revenue guidance to $390–$410 million and set Q4 net revenue guidance at $115–$135 million, while lifting fully synergized pro